Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$11.48
-2.0%
$12.23
$10.45
$21.69
$4.14B0.58671,476 shs427,967 shs
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$21.83
-2.2%
$22.86
$18.70
$29.55
$1.04B2.01389,140 shs786,262 shs
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
$58.60
+5.2%
$55.11
$47.04
$103.81
$3.24B1.1823,507 shs1.08 million shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$73.24
-3.1%
$71.51
$36.93
$80.99
$3.69B-2.67754,299 shs1.22 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
-2.34%+1.71%-0.78%-28.23%-24.62%
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-2.20%+0.23%-9.46%-9.04%+1.11%
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
+5.19%+2.13%+8.56%-8.92%-8.58%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-3.15%-4.75%-2.16%+50.02%+70.76%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
4.1177 of 5 stars
4.12.00.00.02.01.73.8
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.0445 of 5 stars
3.51.00.00.01.82.50.6
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
2.4659 of 5 stars
3.41.00.00.03.52.50.6
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
4.8214 of 5 stars
4.63.00.04.63.43.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
2.25
Hold$15.5035.02% Upside
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
3.00
Buy$31.1742.77% Upside
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
2.86
Moderate Buy$90.0053.58% Upside
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3.11
Buy$106.7845.79% Upside

Current Analyst Ratings Breakdown

Latest BLFS, BLCO, SLNO, and PRCT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/8/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$81.00 ➝ $97.00
5/8/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$102.00 ➝ $105.00
5/6/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$18.00 ➝ $12.00
5/2/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $15.00
5/1/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $13.00
5/1/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $12.00
5/1/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$19.00 ➝ $15.50
4/25/2025
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$104.00 ➝ $84.00
4/24/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/24/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$93.00 ➝ $145.00
(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$4.83B0.84$1.37 per share8.41$18.57 per share0.62
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$87.76M11.82N/AN/A$7.67 per share2.85
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
$249.12M13.01N/AN/A$5.56 per share10.54
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/A$5.16 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
-$317M-$1.03N/A11.960.85-6.62%3.35%1.66%7/30/2025 (Estimated)
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$66.43M-$0.29N/AN/AN/A-38.98%-6.61%-5.54%8/14/2025 (Estimated)
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
-$105.90M-$1.70N/AN/AN/A-50.07%-38.57%-26.06%8/7/2025 (Estimated)
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$38.99M-$4.62N/AN/AN/AN/A-61.99%-55.21%8/6/2025 (Estimated)

Latest BLFS, BLCO, SLNO, and PRCT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$0.03$0.04+$0.07-$0.01$22.22 million$23.94 million
5/7/2025Q1 2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$1.14-$0.95+$0.19-$0.95N/AN/A
4/30/2025Q1 2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$0.03-$0.07-$0.10-$0.60$1.15 billion$1.15 billion
4/24/2025Q1 2025
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
-$0.49-$0.45+$0.04-$0.45$65.39 million$69.16 million
3/5/2025Q4 2024
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$0.86-$1.27-$0.41-$1.27N/AN/A
3/3/2025Q4 2024
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$0.06$0.26+$0.32$0.26$21.73 million$22.71 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
N/AN/AN/AN/AN/A
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
N/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.72
1.60
1.01
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
0.03
2.78
1.78
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
0.21
6.02
5.07
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/A
17.26
17.26

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
11.07%
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
93.24%
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
89.46%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.76%
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.20%
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
6.60%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
12.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
12,500353.43 million351.94 millionOptionable
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
44047.50 million45.37 millionOptionable
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
43055.33 million43.10 millionOptionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3050.39 million37.81 millionOptionable

Recent News About These Companies

HC Wainwright Issues Optimistic Estimate for SLNO Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$11.48 -0.24 (-2.05%)
Closing price 05/30/2025 03:59 PM Eastern
Extended Trading
$11.91 +0.43 (+3.74%)
As of 05/30/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

BioLife Solutions stock logo

BioLife Solutions NASDAQ:BLFS

$21.83 -0.49 (-2.20%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$21.88 +0.05 (+0.21%)
As of 05/30/2025 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

PROCEPT BioRobotics stock logo

PROCEPT BioRobotics NASDAQ:PRCT

$58.60 +2.89 (+5.19%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$57.73 -0.87 (-1.48%)
As of 05/30/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Soleno Therapeutics stock logo

Soleno Therapeutics NASDAQ:SLNO

$73.24 -2.38 (-3.15%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$73.31 +0.07 (+0.09%)
As of 05/30/2025 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.